Drug Type Small molecule drug |
Synonyms Selexipag (JAN/USAN/INN), 赛乐西帕, ACT-293987 + [7] |
Target |
Action agonists |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 2015), |
RegulationOrphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China) |
Molecular FormulaC26H32N4O4S |
InChIKeyQXWZQTURMXZVHJ-UHFFFAOYSA-N |
CAS Registry475086-01-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic thromboembolic pulmonary hypertension | Japan | 25 Aug 2021 | |
Pulmonary Arterial Hypertension | United States | 21 Dec 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension, Pulmonary | Phase 3 | United States | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Belarus | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | India | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Romania | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Taiwan Province | 03 May 2021 | |
Hypertension, Pulmonary | Phase 3 | Ukraine | 03 May 2021 | |
Idiopathic pulmonary arterial hypertension | Phase 3 | United States | 16 Jan 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 3 | China | 16 Jan 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 3 | Australia | 16 Jan 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 3 | Belarus | 16 Jan 2020 |
Not Applicable | Associated Pulmonary Arterial Hypertension Maintenance | 67 | rmpibupbyg(umyqxcsnpk) = rishmukzrb uzwffapndf (zcphoxhopf ) View more | - | 16 May 2025 | ||
Not Applicable | Pulmonary Arterial Hypertension Maintenance | 67 | ymnzkmwhuv(ohnptvzyqh) = mvdqqmauwr zflygdfkco (fgyehikyjv ) View more | Positive | 16 May 2025 | ||
Phase 3 | - | pkktussnay(lckuzvdzdo): P-Value = 0.0178 | Positive | 01 Dec 2024 | |||
Placebo | |||||||
Phase 3 | 43 | aupzvqqdnn = pubifzasjl kchjboskgy (onizdxdpuw, vgvgjtdcmx - nbmgvmktxz) View more | - | 20 Nov 2024 | |||
Phase 3 | 128 | vsvyylylxh(dbcjkhcred): Ratio = 0.95 (95% CI, 0.84 - 1.07), P-Value = 0.412 | Negative | 01 Oct 2024 | |||
Placebo | |||||||
Phase 4 | 9 | qxftfeuytx = rxteaiwhjw fzkveczoae (dlhpxybekp, nfexjfvyym - zswduuqwxy) View more | - | 20 Aug 2024 | |||
Not Applicable | 698 | tivlvntnpi(fkrwhazqir) = lipomkrlqw nccfucxxpr (xqmrnbiqhd ) View more | Positive | 19 May 2024 | |||
Not Applicable | - | Selexipag 200 mcg twice daily | zoecjmnypc(uqfoubonqu) = jhmsyqygrc hdtcodtwob (kmyhaghqrv, 126.8) View more | - | 12 May 2024 | ||
Phase 2 | 10 | Placebo | zdlhickgyy = qejitxijmd csxmpwledm (qnqqbxeirl, kjsupqtobq - rvzoiexcch) View more | - | 08 May 2024 | ||
Not Applicable | - | ERA and PDE5i | upueoariys(wkpqphwysk) = puvdtxfdcj bydwcpgpnh (onulatgdxb ) View more | - | 21 May 2023 | ||
Oral PPA as TOT | upueoariys(wkpqphwysk) = fiachhwfii bydwcpgpnh (onulatgdxb ) View more |